Synagis Description

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Full Prescribing Info

Description

1 mL of Synagis solution contains 100 mg of palivizumab. Palivizumab is a recombinant humanised monoclonal antibody produced by DNA technology in mouse myeloma host cells.
Excipients/Inactive Ingredients: Histidine, glycine, water for injections.

palivizumab

Manufacturer:

AstraZeneca

Distributor:

Zuellig